SEC Comment Letter 0000000000-23-013595 to CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc.
Date: Dec. 13, 2023 · CIK: 0001729427 · Accession: 0000000000-23-013595
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275973
Letter
United States securities and exchange commission logo December 13, 2023 John Climaco Chief Executive Officer CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 Re:CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed December 8, 2023 File No. 333-275973 Dear John Climaco: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Cavas S. Pavri, Esq.
Show Raw Text
United States securities and exchange commission logo
December 13, 2023
John Climaco
Chief Executive Officer
CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027
Re:CNS Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed December 8, 2023
File No. 333-275973
Dear John Climaco:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Cavas S. Pavri, Esq.